Jundishapur J Microbiol
Jundishapur J Microbiol

article information

Jundishapur Journal of Microbiology: Vol.15, issue 3; e118944
published online: May 14, 2022
article type: Research Article
received: August 22, 2021
revised: March 7, 2022
accepted: April 6, 2022
DOI: https://doi.org/10.5812/jjm-118944
Crossmark

Prevalence of Extended-Spectrum β-Lactamase Genes and Antibiotic Resistance Pattern in Clinical Isolates of Acinetobacter baumannii from Patients Hospitalized in Mashhad, Iran

authors:

avatar Hasan Ghali Abdulhasan Alshami 1 , 2 , avatar Maryam Abbasi Shaye ORCID 1 , avatar Masoumeh Bahreini ORCID 1 , avatar Mohammad Reza Sharifmoghadam ORCID 1 , *

Department of Biology, Ferdowsi University of Mashhad, Mashhad, Iran
General Directorate of Education for Maysan Governorate, Ministry of Education, Iraq

how to cite: Alshami H G A, Abbasi Shaye M, Bahreini M, Sharifmoghadam M R. Prevalence of Extended-Spectrum β-Lactamase Genes and Antibiotic Resistance Pattern in Clinical Isolates of Acinetobacter baumannii from Patients Hospitalized in Mashhad, Iran. Jundishapur J Microbiol. 2022;15(3):e118944. https://doi.org/10.5812/jjm-118944.

Abstract

Background:

Carbapenem-resistant Acinetobacter baumannii strains are one of the most severe factors in hospital infection worldwide, in which the beta-lactamase enzyme is one of the main resistance mechanisms.

Objectives:

This study aimed to evaluate the presence of carbapenem-resistant beta-lactamase genes and determine antibiotic resistance patterns in the clinical isolates of A. baumannii from patients hospitalized in the Shahid Kamyab Hospital, Mashhad, Iran.

Methods:

Out of 286 collected isolates from patients hospitalized in Shahid Kamyab Hospital (from March 2017 to June 2017), 31 isolates were confirmed to be A. baumannii using biochemical tests. Antibiotic susceptibility testing was conducted using the disc diffusion method according to the CLSI standard protocols. The presence of beta-lactamase genes, namely blaVEB, blaPER, blaAmpC, blaVIM, blaIMP, blaSHV, and blaTEM, was detected using polymerase chain reaction.

Results:

In this study, 31 isolates were identified as A. baumannii, all of which revealed high resistance to ceftazidime, cefixime, ceftriaxone, meropenem, imipenem, cefotaxime and cephalexin. In this case, the lowest resistance (19.35%) was observed against polymixin B. Moreover, blaAmpC, blaTEM, blaSHV, blaPER, and blaVIM were observed in 93.54% (29), 51.61% (16), 48.38% (15), 41.93% (13), and 77% (24) of the isolates, respectively. However, blaVEB and blaIMP were observed in none of the isolates.

Conclusions:

The results showed high carbapenem resistance and high frequency of beta-lactamase resistance genes among the clinical isolates of A. baumannii.

1. Background

Acinetobacter is a Gram-negative pathogen, whose potentials in inducing various nosocomial infections in immunocompromised patients has attracted much attention worldwide (1). Before 1970, Acinetobacter baumannii was sensitive to most antibiotics, including extended-spectrum beta-lactams (ESBL). However, its capability to acquire resistance genes posed considerable problems in antimicrobial treatments (1, 2). Nowadays, A. baumannii is one of the six most crucial multidrug-resistant (MDR) bacteria in hospitals worldwide (3). Antibiotic resistance is a worldwide threat with an increasing trend and high mortality rates (4), which is rapidly increasing among clinical isolates, especially Acinetobacter spp., Klebsiella spp., Pseudomonas aeruginosa, Proteus spp., Escherichia coli, and Enterobacter spp., because of mobile genetic elements (MGE). Accordingly, isolating resistant bacteria and identifying their resistance mechanisms seem to be crucial. Quick and reliable results are required to apply appropriate therapeutic strategies and prevent the spread of resistance factors in hospitals and the environment (5).

Beta-lactam antibiotics are a large class of antibiotics containing the β-lactam ring in their structure and include penicillins, cephalosporins, monobactams, and carbapenems. Carbapenems are often used as the last line to treat infections caused by MDR Gram-negative bacilli (6). Carbapenems are bactericidal agents acting quickly to kill bacteria and having a more comprehensive range of antimicrobial activities than other antibiotics. These antibiotics (except for Ertapenem) are active against clinically-pathogenic bacteria such as P. aeruginosa, Burkholderia cepacia, and Acinetobacter spp. (7). For years, carbapenems have been an option for treating different infections caused by A. baumannii. Recently, resistance to carbapenems has increased among the clinical and environmental isolates of A. baumannii. (8). Resistance to carbapenems happens through the production of VIM, IMP, NDM, and SIM metallo-beta-lactamases (carbapenems) or non-metallo-carbapenems (9, 10).

The IMP, AmpC, VIM, and TEM beta-lactamase genes are more common in Gram-negative bacteria, while the PER, VEB, and SHV beta-lactamase genes are rarely noticed (10, 11). It is of paramount importance to study these genes since they can be transferred among widely different bacteria from one region and country to another through MGE (10). Accordingly, the regular/periodic investigation of the antibiotic-resistant pattern is necessary to control and reduce emerging new antimicrobial resistance.

2. Objectives

The present study aimed to determine antibiotic-resistant patterns and evaluate the presence of Carbapenem-resistant beta-lactamase genes in the clinical isolates of A. baumannii from patients referred to the Shahid Kamyab Hospital, Mashhad, Iran.

3. Methods

3.1. Sample Collection and Identification

In this study, 286 samples were collected and identified using the GNA macrogen from patients admitted to different wards of Shahid Kamyab Hospital in Mashhad from March 2017 to June 2017. Among the collected samples, 31 samples were confirmed to be A. baumannii.

3.2. Antimicrobial Susceptibility Tests

Antibacterial susceptibility testing was performed using the disk-diffusion (Kirby-Bauer) method according to the Clinical and Laboratory Standards Institute (CLSI, 2014) guidelines (12). Thirteen antimicrobial agents (HiMedia, India) in this study were Imipenem (10 µg), meropenem (10 µg), amikacin (30 µg), ceftriaxone (30µg), ciprofloxacin (5 µg), cefixime (5 µg), polymyxin b (300 units), gentamicin (10 µg), ceftazidime (30 µg), cefotaxime (30 µg), amoxiclav-co-trimoxazole (20/10 µg) and cephalexin (30 µg). Moreover, the isolates were categorized as sensitive, intermediate, and resistant.

3.3. DNA Extraction

The DNA extraction was performed using the boiling method. The extracted DNAs were stored at 4°C. Aliquots of 2 μL of template DNA were used for PCR.

3.4. Polymerase Chain Reaction

The distribution of beta-lactamase genes, namely blaAmpC, blaPER, blaVEB, blaTEM, blaVIM, blaIMP, and blaSHV, were investigated in all A. baumannii isolates by polymerase chain reaction (PCR) using Taq DNA polymerase master mix (Amplicon, Denmark). The primer sequences (Microgen, South Korea) presented in Table 1 were adopted from previous studies. The PCR conditions were as follows: initial denaturation at 95°C for 5 minutes, 30 cycles with denaturation at 94°C for 1 minute, 30-second annealing at 54.5°C for blaSHV and blaVEB, at 50°C for blaAmpC and blaPER, at 56°C, 54°C, and 51°C for blaIMP, blaTEM and blaVIM, respectively, extension at 72°C for 1 minute, followed by final extension at 72°C for 10 minutes (Bio-rad, Germany).

Table 1.

Primers’ Characteristics

Gene and Primers' SequencesTM (°C)Length (bp)Reference
blaAmpC663(13)
Forward5'- ACTTACTTCAACTCGCGACG -3'50
Reverse5'- TAAACACCACATATGTTCCG -3'50
blaVIM390(14)
Forward5'- GATGGTGTTTGGTCGCATA -3'51
Reverse5'- CGAATGCGCAGCACCAG -3'51
blaIMP1150(15)
Forward5'- CATGGTTTGGTGGTTCTTGT -3'56
Reverse5'- ATAATTTGGCGGACTTTGGC -3'56
blaTEM535(16)
Forward5'- AGGAAGAGTATGATTCAACA -3'54
Reverse5'- CTCGTCGTTTGGTATGGC -3'54
blaPER520(14)
Forward5'- GCTCCGATAATGAAAGCGT -3'50
Reverse5'- TTCGGCTTGACTCGGCTGA -3'50
blaVEB648(14)
Forward5'- CATTTCCCGATGCAAAGCGT -3'54.5
Reverse5'- CGAAGTTTCTTTGGACTCTG -3'54.5
blaSHV713(17)
Forward5'- AGCCGCTTGAGCAAATTAAAC- 3'54.5
Reverse5'- ATCCCGCAGATAAATCACCAC- 3'54.5

3.5. Gel Electrophoresis

Finally, 5 μL of PCR product and a 100 bp DNA ladder was electrophoresed using 1% agarose gel to confirm the PCR amplification.

4. Results

4.1. Identification of Bacterial Isolates

Out of 286 isolates (Table 2), 31 isolates (70.96% from males and 29.03% from females) were A. baumannii. The A. baumannii isolates were isolated from the patients’ wound (n = 10), lungs (n = 10), throats (n = 4), blood (n = 3), bronchi (n = 2), catheters (n = 1), and cerebrospinal fluid (n = 1). Table 3 presents the sources of the isolates, according to which the highest infection source is for intensive care units (ICUs) (77.41%).

Table 2.

Frequency and Type of Collected Bacteria from Different Wards of Hospital

BacteriaNo. (%)
Acinetobacter baumannii31 (10.83)
A. heamolyticus3 (1.04)
Klebsiella pneumoniae37 (12.93)
Enterobacter18 (6.29)
Seratia2 (0.69)
Pseudomonas63 (22.02)
Escherichia coli57 (19.93)
Staphylococcus49 (17.13)
Proteus mirabilis15 (5.24)
Enterococci8 (2.79)
Unknown3 (1.04)
Total286 (100)
Table 3.

Frequency and Percentage of Genes and Acinetobacter baumannii Isolates from Different Wards of the Hospital a

WardsICUWomenNeurologyOrthopedics
Isolates genes24 (77.42)3 (9.68)2 (6.45)2 (6.45)
AmpC22 (91.66) 3 (100) 2 (100)2 (100)
VIM17 (70.83)3 (100) 2 (100)2 (100)
TEM13 (54.16) 2 (66.66) 0 (0)1 (50)
PER8 (33.33)2 (66.66) 2 (100) 1 (50)
SHV11 (45.83) 1 (33.33) 2 (100) 1 (100)
VEB0 (0) 0 (0) 0 (0)0 (0)
IMP0 (0)0 (0) 0 (0) 0 (0)

a Values are expressed as No. (%).

4.2. Antibiotic Susceptibility Tests

Table 4 shows the antibiotic resistance patterns in the A. baumannii isolates. All isolates were MDR and revealed resistance to most of the tested antibiotics. The highest resistance level (100%) was observed against imipenem, meropenem, ceftazidime, ceftriaxone, cefixime, cefotaxime, and cephalexin. On the other hand, the lowest resistance level was observed against polymyxin B (19.35%). Notably, 92.3% of the isolates were resistant to at least six classes (out of seven) of the antibiotics (MDR).

Table 4.

Resistance and Sensitivity Frequency and Percentage of Acinetobacter baumannii Isolates to Different Antibiotics a

Antibiotic ClassResistantIntermediateSensitive
Carbapenems
Imipenem (10 µg)31 (100)0 (0)0 (0)
Meropenem (10 µg)31 (100)0 (0)0 (0)
Cephalosporins
Ceftazidime (30 µg)31 (100)0 (0)0 (0)
Ceftriaxone (30 µg)31 (100)0 (0)0 (0)
Cefixime (5 µg)31 (100)0 (0)0 (0)
Cefotaxim (30 µg)31 (100)0 (0)0 (0)
Cephalexin (30 µg)31 (100)0 (0)0 (0)
Quinolones
Ciprofloxacin (5 µg)29 (93.54)0 (0)2 (6.45)
Polymixin
Polymyxin B (300 unit)6 (19.35)3 (11.50)22 (70.96)
Aminoglycosides
Gentamicin (10 µg)25 (80.64)0 (0)6 (19.35)
Amikacin (30 µg)22 (70.96)1 (3.8)8 (25.80)
Penicillin
Amoxyclave (20/10 µg)30 (96.77)0 (0)1 (3.22)
Sulfonamides
Co-tri-moxazol (1.25/23.75 µg)24 (77.41)2 (7.70)5 (16.12)

a Values are expressed as No. (%).

4.3. Determination of Beta-Lactamase Genes

In this study, blaAmpC, blaVIM, blaTEM, blaSHV, and blaPER were observed in 29 (93.54%), 24 (77%), 16 (51.61%), 15 (48.38%), and 13 (41.93%) A. baumannii isolates, respectively. However, blaVEB and blaIMP genes were found in none of the isolates (0%). Fourteen genotypic patterns were observed among the A. baumannii isolates (Table 5). According to the results, all isolates harbored at least one gene, indicating that the studied beta-lactamase genes were 100% involved in antibiotic resistance. The distribution rates of beta-lactamase genes among the concerned isolates were as follows: One gene in two isolates, two genes in six isolates, three genes in 11 isolates, four genes in 10 isolates, and five genes in two isolates. However, none of the isolates contained six or seven genes together. The highest frequency (n = 26) belonged to the AmpC and VIM genes, and the lowest frequency (n = 13) belonged to the PER gene. Tables 3 and 6 show the frequency of the genotypic pattern and the frequency distribution of genes in the A. baumannii isolates by the type of clinical samples and hospital wards, respectively. Accordingly, the AmpC and VIM were the most frequent genes in the wound and lung samples from the ICU wards. Finally, the results also indicated that group A and C beta-lactamases were with the highest frequency in the isolates.

Table 5.

Prevalence of Different Genotypic Patterns of Beta-Lactamase Genes in Acinetobacter baumannii Isolates

GenotypeFrequency Percentage
1TEM1 (3.22)
2AmpC1 (3.22)
3TEM, AmpC3 (9.67)
4SHV, VIM1 (3.22)
5AmpC, VIM2 (6.45)
6SHV, AmpC, VIM3 (9.67)
7TEM, AmpC, VIM3 (9.67)
8PER, AmpC, VIM3 (9.67)
9PER, TEM, AmpC1 (3.22)
10SHV, TEM, AmpC1 (3.22)
11PER, TEM, AmpC, VIM2 (6.45)
12PER, SHV, AmpC, VIM5 (16.12)
13SHV, TEM, AmpC, VIM3 (9.67)
14PER, SHV, TEM, AmpC, VIM2 (6.45)
Table 6.

Frequency Distribution of Genes in Acinetobacter baumannii Isolates by Type of Clinical Samples a

GeneBronchiThroatLungBloodWoundCathetersCSF
AmpC2 (100)4 (100)9 (90)3 (100)9 (90)1 (100)1 (100)
VIM2 (100)4 (100)7 (70)2 (66)8 (80)1 (100)0 (0)
TEM2 (100)2 (50)4 (40)3 (100)4 (40)0 (0)1 (100)
SHV0 (0)1 (25)6 (60)1 (33.3)6 (60)1 (100)0 (0)
PER0 (0)1 (25)4 (40)1 (33.3)5 (50)1 (100)1 (100)
VEB0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)
IMP0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)

a Values are expressed as No. (%).

5. Discussion

This study aimed to determine antibiotic resistance patterns and investigate the presence of beta-lactamase genes in the clinical isolates of A. baumannii. According to the findings, the most significant proportion of the A. baumannii isolates was from males and the ICU ward of the hospital. This finding is in agreement with the findings of other researchers, including Sharif et al. and Shoja et al. in Iran, Chang et al. and Liu and Liu in China, and Aksoy et al. in Turkey (13, 18-21). The A. baumannii isolates were isolated the most from the wound and lung samples and the least from cerebrospinal fluid and catheters, which is consistent with Aghamiri et al.’s study in Tehran, Iran (22).

Resistance to carbapenems (imipenem and meropenem) and cephalosporins (ceftazidime, ceftriaxone, cefixime, cefotaxime and cephalexin) was observed in all A. baumannii isolates. The imipenem-resistance isolates of A. baumannii were reported to be 26.7, 54, and 100% in studies by Khosroshahi and Sharifi, Peymani et al. and Ibrahimagić et al., respectively (23-25). Resistance to imipenem increased over time from 26.7% in 2007 to 100% in 2017. In the studies conducted in different regions of the world by Peymani et al., Sharif et al., Zarifi et al., Ibrahimagić et al., Al-Hassan and Al-Madboly, and Khuntayaporn et al., 56, 82, 98.6, 30.8, 81, and 98% of A. baumannii isolates exhibited resistance to Meropenem, respectively (18, 24-28). Similarly, resistance to meropenem increased over time from 26.7% in 2011 to 100% in 2021. The comparison of the results indicates that antibiotic resistance is growing over time (29), which could be due to the inappropriate use and the overuse of antibiotics in previous years as well as the increasing prevalence of beta-lactamase genes. Accordingly, antimicrobial therapies have become less effective.

High resistance to carbapenems could be alarming as these antibiotics are often used as the last resort to treat life-threatening infections in humans. In the present study, resistance to Imipenem and meropenem (100%) was considerably higher than values reported in previous studies in different parts of Iran and lower than the results recently reported by Khuntayaporn et al. in Thailand (28). Resistance to polymyxin B was reported to be 0, 10.9, 11, and 16% in A. baumannii isolates by Shoja et al., Abbasi Shaye et al., Saranathan et al., and Ahdi Khosroshahi et al. respectively (19, 30-32). Furthermore, the lowest resistance in the present study was observed against polymyxin B (19.35%).

The PCR results of the present study showed that all isolates contained at least one beta-lactamase gene. The AmpC gene, belonging to the class C beta-lactamases with 93.54%, was the most commonly observed beta-lactamase gene in this study. This finding is in line with those studies reporting the high prevalence of this gene among the clinical isolates of A. baumannii in different regions (13, 33-35). The VIM and the IMP genes are associated with the class B beta-lactamases; however, IMP is not frequently found in A. baumannii isolates regarding the prevalence of beta-lactamase genes. In the present study, the IMP gene was found in none of the isolates, which is in accordance with several studies conducted in Iran and other countries (13, 14, 16, 21, 24, 27, 33, 36, 37).

Previous studies have revealed the low prevalence of VIM; however, it was frequently observed in the A. baumannii isolates in the present study (77%), indicating its increasing prevalence over time. The VIM gene was found in none of the A. baumannii isolates studied by Shoja et al. in Ahvaz, Iran, from 2010 to 2013 (19, 36, 37). However, Farajzadeh Sheikh et al. reported the presence of VIM in 31.4% of A. baumannii isolates in Ahvaz, Iran (38). Moreover, the prevalence of VIM in A. baumannii was reported to be 17.44, 31.4, 36%, 40, and 86% in different countries (22, 38-41). Class A beta-lactamase genes, including SHV, TEM, PER, and VEB, showed different prevalence rates in the A. baumannii isolates (48.38, 51.61, 41.93, and 0%, respectively). Accordingly, VEB was noticed in none of the A. baumannii isolates, which is in accordance with many other studies (14, 25, 34, 42).

Previous studies have reported an increase in the prevalence of SHV in A. baumannii, indicating that it was previously more common in Enterobacteriaceae (43). The prevalence rates of TEM and PER in the present study were 51.61 and 41.93, respectively. This finding is not in line with the findings reported by Zarifi et al. in Mashhad, Iran as they reported the prevalence of TEM and PER in A. baumannii samples to be 27.1 and 7.1%, respectively, showing that an increase in the prevalence of TEM and PER in the clinical isolates of A. baumannii (26). Abdar et al. also reported an increase in the prevalence of TEM (42%) in A. baumannii strains isolated from nosocomial infections in Tehran, Iran (42). The findings indicated that most isolates were resistant to most of the concerned antimicrobials, and that about 92.3% of the isolates were resistant to more than six classes of antibiotics, classified in the MDR group. Moreover, all isolates showed resistance at least to one of the studied antibiotics. The presence of at least one beta-lactamases gene in all isolates confirms the high prevalence of resistance to these antibiotics.

5.1. Conclusions

In conclusion, the findings showed an increase in resistance to some antibiotics, including carbapenems and cephalosporins, reflecting that the high prevalence of beta-lactamase genes among A. baumannii isolates is probably due to the excessive and improper use of antimicrobial agents by patients. The findings also indicated that the highest prevalence rates in the concerned isolates were related to groups A and C beta-lactamases. The high resistance of the isolates to antibiotics indicates the necessity of detecting resistant strains rapidly and timely to select appropriate treatment options and prevent the spread of resistance. Moreover, it is recommended to treat nosocomial infections according to the regional patterns of sensitivity and resistance to prevent the spread of drug-resistant strains.

Acknowledgements

References

  • 1.

    Evans BA, Hamouda A, Amyes SG. The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des. 2013;19(2):223-38. [PubMed ID: 22894617].

  • 2.

    Buyuk A, Yilmaz FF, Gul Yurtsever S, Hosgor Limoncu M. Antibiotic resistance profiles and genotypes of Acinetobacter baumannii isolates and in vitro interactions of various antibiotics in combination with tigecycline and colistin. Turk J Pharm Sci. 2017;14(1):13-8. [PubMed ID: 32454589]. [PubMed Central ID: PMC7228003]. https://doi.org/10.4274/tjps.44127.

  • 3.

    Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: Evolution of a global pathogen. Pathog Dis. 2014;71(3):292-301. [PubMed ID: 24376225]. https://doi.org/10.1111/2049-632X.12125.

  • 4.

    Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2019;63(1). [PubMed ID: 30323035]. [PubMed Central ID: PMC6325237]. https://doi.org/10.1128/AAC.01110-18.

  • 5.

    Georgios M, Egki T, Effrosyni S. Phenotypic and molecular methods for the detection of antibiotic resistance mechanisms in gram negative nosocomial pathogens. In: Saxena S, editor. Trends in Infectious Diseases. London, UK: IntechOpen; 2014. https://doi.org/10.5772/57582.

  • 6.

    Mate P, Sulochana Devi K, Mamta Devi K, Damrolien S, Lilavati Devi N, Devi PP. Prevalence of carbapenem resistance among Gram-negative bacteria in a tertiary care hospital in north-east India. IOSR J Dent Med Sci. 2014;13(12):56-60. https://doi.org/10.9790/0853-131235660.

  • 7.

    Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect. 2008;14(12):1102-11. [PubMed ID: 19076841]. https://doi.org/10.1111/j.1469-0691.2008.02101.x.

  • 8.

    Wu T. Carbapenem-resistant or multidrug-resistant acinetobacter baumannii-a clinician's perspective. The Hong Kong Medical. 2011;16(4).

  • 9.

    Kao C, Wu JJ. [Carbapenem resistance: Epidemiology, mechanisms and screening methods]. J Biomed Lab Sci. 2015;27(1):1-9. Chinese.

  • 10.

    Satir S, Elkhalifa A, Ali M, El Hussein A, Elkhidir I. Detection of Carbepenem resistance genes among selected Gram Negative bacteria isolated from patients in-Khartoum State, Sudan. Clin. Microbiol. 2016;5(6):2-4. https://doi.org/10.4172/2327-5073.

  • 11.

    Fazeli H, Kamali Dolatabadi R, Taraghian A, Nasr Isfahani B, Moghim S. Genetic characterization of blaSHV/VEB/PER genes in ESBL-producing MDR Klebsiella Pneumonia strains isolated from patients in Isfahan, Iran. Eur Online J Nat Soc Sci. 2015;4(1):191-202.

  • 12.

    Patel JB, Weinstein MP, Clinical; Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Malvern, PA, United States: Clinical and Laboratory Standards Institute; 2020.

  • 13.

    Chang Y, Luan G, Xu Y, Wang Y, Shen M, Zhang C, et al. Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital. Front Microbiol. 2015;6:910. [PubMed ID: 26388854]. [PubMed Central ID: PMC4555021]. https://doi.org/10.3389/fmicb.2015.00910.

  • 14.

    Lowings M, Ehlers MM, Dreyer AW, Kock MM. High prevalence of oxacillinases in clinical multidrug-resistant Acinetobacter baumannii isolates from the Tshwane region, South Africa - an update. BMC Infect Dis. 2015;15:521. [PubMed ID: 26573617]. [PubMed Central ID: PMC4647659]. https://doi.org/10.1186/s12879-015-1246-8.

  • 15.

    Radu-Popescu MA, Dumitriu S, Enache-Soare S, Bancescu G, Udristoiu A, Cojocaru M, et al. Phenotypic and genotypic characterization of antibiotic resistance patterns in Acinetobacter baumannii strains isolated in a Romanian hospital. Farmacia. 2010;58(3):362-7.

  • 16.

    Yin XL, Hou TW, Xu SB, Ma CQ, Yao ZY, Li W, et al. Detection of drug resistance-associated genes of multidrug-resistant Acinetobacter baumannii. Microb Drug Resist. 2008;14(2):145-50. [PubMed ID: 18489241]. https://doi.org/10.1089/mdr.2008.0799.

  • 17.

    Hamdy Mohammed el S, Elsadek Fakhr A, Mohammed El Sayed H, Al Johery SA, Abdel Ghani Hassanein W. Spread of TEM, VIM, SHV, and CTX-M beta-lactamases in imipenem-resistant Gram-negative bacilli isolated from Egyptian hospitals. Int J Microbiol. 2016;2016:8382605. [PubMed ID: 27123005]. [PubMed Central ID: PMC4830709]. https://doi.org/10.1155/2016/8382605.

  • 18.

    Sharif M, Mirnejad R, Amirmozafari N. Molecular identification of TEM and SHV extended spectrum $\beta$-lactamase in clinical isolates of Acinetobacter baumannii from Tehran hospitals. The J Gen Microb Immun. 2014;2:1-9. https://doi.org/10.5899/2014/jgmi-00020.

  • 19.

    Shoja S, Moosavian M, Rostami S, Abbasi F, Tabatabaiefar MA, Peymani A. Characterization of oxacillinase and metallo-beta-lactamas genes and molecular typing of clinical isolates of Acinetobacter baumannii in Ahvaz, South-West of Iran. Jundishapur J Microbiol. 2016;9(5). e32388. [PubMed ID: 27540456]. [PubMed Central ID: PMC4976075]. https://doi.org/10.5812/jjm.32388.

  • 20.

    Liu Y, Liu X. Detection of AmpC beta-lactamases in Acinetobacter baumannii in the Xuzhou region and analysis of drug resistance. Exp Ther Med. 2015;10(3):933-6. [PubMed ID: 26622417]. [PubMed Central ID: PMC4533231]. https://doi.org/10.3892/etm.2015.2612.

  • 21.

    Aksoy MD, Cavuslu S, Tugrul HM. Investigation of metallo beta lactamases and oxacilinases in carbapenem resistant Acinetobacter baumannii strains isolated from inpatients. Balkan Med J. 2015;32(1):79-83. [PubMed ID: 25759776]. [PubMed Central ID: PMC4342142]. https://doi.org/10.5152/balkanmedj.2015.15302.

  • 22.

    Aghamiri S, Amirmozafari N, Fallah Mehrabadi J, Fouladtan B, Hanafi Abdar M. Antibiotic resistance patterns and a survey of metallo-beta-lactamase genes including bla-IMP and bla-VIM Types in Acinetobacter baumannii isolated from hospital patients in Tehran. Chemotherapy. 2016;61(5):275-80. [PubMed ID: 27058056]. https://doi.org/10.1159/000443825.

  • 23.

    Khosroshahi N, Sharifi M. [Isolation of carbapenem resistant Acinetobacter baumannii (CRAB) strains from patients and equipments of Intensive care units (ICUs) at Qazvin between 2005-2006]. Iranian J Med Microbiol. 2007;1(3):33-8. Persian.

  • 24.

    Ibrahimagic A, Kamberovic F, Uzunovic S, Bedenic B, Idrizovic E. Molecular characteristics and antibiotic resistance of Acinetobacter baumanniibeta-lactamase-producing isolates, a predominance of intrinsic blaOXA-51, and detection of TEM and CTX-M genes. Turk J Med Sci. 2017;47(2):715-20. [PubMed ID: 28425271]. https://doi.org/10.3906/sag-1507-180.

  • 25.

    Peymani A, Nahaei MR, Farajnia S, Hasani A, Mirsalehian A, Sohrabi N, et al. High prevalence of metallo-beta-lactamase-producing acinetobacter baumannii in a teaching hospital in Tabriz, Iran. Jpn J Infect Dis. 2011;64(1):69-71. [PubMed ID: 21266761].

  • 26.

    Zarifi E, Eslami G, Khaledi A, Vakili M, Vazini H, Zandi H. Prevalence of ESBLs in Acinetobacter baumannii isolated from intensive care unit (ICU) of Ghaem hospital, Mashhad, Iran. J Pure Appl Microbiol. 2017;11(2):811-9.

  • 27.

    Al-Hassan LL, Al-Madboly LA. Molecular characterisation of an Acinetobacter baumannii outbreak. Infect Prev Pract. 2020;2(2):100040. [PubMed ID: 34368692]. [PubMed Central ID: PMC8336282]. https://doi.org/10.1016/j.infpip.2020.100040.

  • 28.

    Khuntayaporn P, Kanathum P, Houngsaitong J, Montakantikul P, Thirapanmethee K, Chomnawang MT. Predominance of international clone 2 multidrug-resistant Acinetobacter baumannii clinical isolates in Thailand: a nationwide study. Ann Clin Microbiol Antimicrob. 2021;20(1):19. [PubMed ID: 33743736]. [PubMed Central ID: PMC7980754]. https://doi.org/10.1186/s12941-021-00424-z.

  • 29.

    Allami M, Bahreini M, Sharifmoghadam MR. Antibiotic resistance, phylogenetic typing, and virulence genes profile analysis of uropathogenic Escherichia coli isolated from patients in southern Iraq. J Appl Genet. 2022;63(2):401-12. [PubMed ID: 35143031]. https://doi.org/10.1007/s13353-022-00683-2.

  • 30.

    Abbasi Shaye M, Sharifmoghadam MR, Bahreini M, Ghazvini K, Mafinezhad A, Amiri G. Study of the role of efflux pumps in amikacin-resistant Acinetobacter isolates from teaching hospitals of Mashhad, Iran. Jundishapur J. Microbiol. 2018;11(4). https://doi.org/10.5812/jjm.12754.

  • 31.

    Saranathan R, Vasanth V, Vasanth T, Shabareesh PR, Shashikala P, Devi CS, et al. Emergence of carbapenem non-susceptible multidrug resistant Acinetobacter baumannii strains of clonal complexes 103(B) and 92(B) harboring OXA-type carbapenemases and metallo-beta-lactamases in Southern India. Microbiol Immunol. 2015;59(5):277-84. [PubMed ID: 25726848]. https://doi.org/10.1111/1348-0421.12252.

  • 32.

    Ahdi Khosroshahi S, Farajnia S, Azhari F, Hosseini MK, Khanipour F, Farajnia H, et al. Antimicrobial susceptibility pattern and prevalence of extended-spectrum _-lactamase genotypes among clinical isolates of Acinetobacter baumanii in Tabriz, North-West of Iran. Jundishapur J Microbiol. 2017;10(6). https://doi.org/10.5812/jjm.13368.

  • 33.

    Al-Agamy MH, Khalaf NG, Tawfick MM, Shibl AM, El Kholy A. Molecular characterization of carbapenem-insensitive Acinetobacter baumannii in Egypt. Int J Infect Dis. 2014;22:49-54. [PubMed ID: 24607428]. https://doi.org/10.1016/j.ijid.2013.12.004.

  • 34.

    Farshadzadeh Z, Hashemi FB, Rahimi S, Pourakbari B, Esmaeili D, Haghighi MA, et al. Wide distribution of carbapenem resistant Acinetobacter baumannii in burns patients in Iran. Front Microbiol. 2015;6:1146. [PubMed ID: 26539176]. [PubMed Central ID: PMC4611150]. https://doi.org/10.3389/fmicb.2015.01146.

  • 35.

    Sarhaddi N, Soleimanpour S, Farsiani H, Mosavat A, Dolatabadi S, Salimizand H, et al. Elevated prevalence of multidrug-resistant Acinetobacter baumannii with extensive genetic diversity in the largest burn centre of northeast Iran. J Glob Antimicrob Resist. 2017;8:60-6. [PubMed ID: 28011349]. https://doi.org/10.1016/j.jgar.2016.10.009.

  • 36.

    Shoja S, Moosavian M, Peymani A, Tabatabaiefar MA, Rostami S, Ebrahimi N. Genotyping of carbapenem resistant Acinetobacter baumannii isolated from tracheal tube discharge of hospitalized patients in intensive care units, Ahvaz, Iran. Iran J Microbiol. 2013;5(4):315-22. [PubMed ID: 25848498]. [PubMed Central ID: PMC4385154].

  • 37.

    Shoja S, Moosavian M, Rostami S, Farahani A, Peymani A, Ahmadi K, et al. Dissemination of carbapenem-resistant Acinetobacter baumannii in patients with burn injuries. J Chin Med Assoc. 2017;80(4):245-52. [PubMed ID: 28268175]. https://doi.org/10.1016/j.jcma.2016.10.013.

  • 38.

    Farajzadeh Sheikh A, Savari M, Abbasi Montazeri E, Khoshnood S. Genotyping and molecular characterization of clinical Acinetobacter baumannii isolates from a single hospital in Southwestern Iran. Pathog Glob Health. 2020;114(5):251-61. [PubMed ID: 32552452]. [PubMed Central ID: PMC7480470]. https://doi.org/10.1080/20477724.2020.1765124.

  • 39.

    Fallah F, Noori M, Hashemi A, Goudarzi H, Karimi A, Erfanimanesh S, et al. Prevalence of bla NDM, bla PER, bla VEB, bla IMP, and bla VIM Genes among Acinetobacter baumannii Isolated from Two Hospitals of Tehran, Iran. Scientifica (Cairo). 2014;2014:245162. [PubMed ID: 25133013]. [PubMed Central ID: PMC4123593]. https://doi.org/10.1155/2014/245162.

  • 40.

    Moghadam MN, Motamedifar M, Sarvari J, Sedigh ES, Mousavi SM, Moghadam FN. Emergence of multidrug resistance and metallobeta-lactamase producing Acinetobacter baumannii Isolated from patients in Shiraz, Iran. Ann Med Health Sci Res. 2016;6(3):162-7. [PubMed ID: 27398247]. [PubMed Central ID: PMC4924489]. https://doi.org/10.4103/2141-9248.183946.

  • 41.

    Nogbou ND, Phofa DT, Nchabeleng M, Musyoki AM. Investigating multi-drug resistant Acinetobacter baumannii isolates at a tertiary hospital in Pretoria, South Africa. Indian J Med Microbiol. 2021;39(2):218-23. [PubMed ID: 33832811]. https://doi.org/10.1016/j.ijmmb.2021.03.005.

  • 42.

    Abdar MH, Taheri-Kalani M, Taheri K, Emadi B, Hasanzadeh A, Sedighi A, et al. Prevalence of extended-spectrum beta-lactamase genes in Acinetobacter baumannii strains isolated from nosocomial infections in Tehran, Iran. GMS Hyg Infect Control. 2019;14:Doc02. [PubMed ID: 30834190]. [PubMed Central ID: PMC6388673]. https://doi.org/10.3205/dgkh000318.

  • 43.

    Al-Hassan L, El Mehallawy H, Amyes SG. Diversity in Acinetobacter baumannii isolates from paediatric cancer patients in Egypt. Clin Microbiol Infect. 2013;19(11):1082-8. [PubMed ID: 23413888]. https://doi.org/10.1111/1469-0691.12143.